23andMe Holding (ME) Financials: History & Chart

23andMe Holding Co. (ME)ME23andMe Holding Co.

About 23andMe Holding Co.

23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.

South San Francisco, CA

560 employees

www.23andme.org

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Joseph Selsavage

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024	Quarter ended Mar 2024	Quarter ended Dec 2023	Quarter ended Sep 2023
Revenue	174.90M	25.42M	45.15M	60.26M	44.07M	40.41M	64.03M	44.75M	50.00M
Cost of Goods Sold	81.63M	11.89M	27.64M	20.44M	21.66M	19.90M	37.00M	24.81M	28.27M
Gross Profit	93.28M	13.53M	17.51M	39.83M	22.41M	20.51M	27.03M	19.94M	21.73M
Gross Profit Margin	53.3%	53.2%	38.8%	66.1%	50.8%	50.8%	42.2%	44.6%	43.5%
Total Operating Expenses	308.96M	44.24M	116.08M	65.06M	83.58M	86.68M	85.95M	93.53M	100.86M
Research & Development	97.25M	14.45M	21.54M	20.22M	41.04M	42.76M	46.72M	41.72M	54.59M
Selling, General & Administrative	156.16M	29.79M	42.73M	43.35M	40.29M	43.93M	37.87M	59.13M	40.46M
Operating Income (EBIT)	-199.39M	-30.71M	-98.57M	-8.94M	-61.17M	-71.95M	-58.92M	-80.91M	-79.13M
Operating Margin	-114.0%	-120.8%	-218.3%	-14.8%	-138.8%	-178.0%	-92.0%	-180.8%	-158.3%
Income Before Tax (EBT)	-196.47M	-30.64M	-99.35M	-7.35M	-59.14M	-69.40M	-208.82M	-277.96M	-75.23M
Interest Income	4.11M	86K	732K	1.28M	2.01M	2.57M	3.04M	3.23M	3.75M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	2.92M	74K	-774K	1.60M	2.02M	2.56M	-149.90M	-197.04M	1.24M
Net Income	-235.31M	-23.83M	-99.35M	-53.03M	-59.10M	-69.40M	-208.84M	-277.98M	-75.27M
Income Tax Expense	-6.85M	-6.81M	0.00	0.00	-41K	0.00	18K	19K	36K
Net Profit Margin	-134.5%	-93.7%	-220.0%	-88.0%	-134.1%	-171.7%	-326.2%	-621.2%	-150.5%
EBITDA	-177.76M	-26.64M	-92.89M	-3.81M	-54.42M	-66.17M	-52.98M	-73.60M	-71.02M
EBITDA Margin	-101.6%	-104.8%	-205.7%	-6.3%	-123.5%	-163.7%	-82.7%	-164.5%	-142.0%
Depreciation & Amortization	21.63M	4.07M	5.68M	5.14M	6.75M	5.79M	5.94M	7.32M	8.11M
EPS Basic	-9.05	-0.87	-3.85	-2.01	-2.32	-2.80	-8.59	-11.56	-3.17
EPS Diluted	-9.05	-0.87	-3.85	-2.01	-2.32	-2.80	-8.59	-11.56	-3.17
Shares Outstanding	27.49M	27.49M	25.82M	26.35M	25.52M	24.79M	24.30M	24.04M	23.74M
Diluted Shares Outstanding	27.49M	27.49M	25.82M	26.35M	25.52M	24.79M	24.30M	24.04M	23.74M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	03/31/2025	03/31/2024	03/31/2023	03/31/2022	03/31/2021	03/31/2020	03/31/2019
Revenue	189.90M	219.64M	299.49M	271.89M	243.92M	305.46M	440.90M
Cost of Goods Sold	89.89M	120.26M	164.99M	138.95M	126.91M	168.03M	257.91M
Gross Profit	100.00M	99.38M	134.50M	132.94M	117.01M	137.43M	182.99M
Gross Profit Margin	52.7%	45.2%	44.9%	48.9%	48.0%	45.0%	41.5%
Total Operating Expenses	340.64M	420.73M	458.51M	387.10M	302.20M	351.19M	371.77M
Research & Development	101.59M	205.36M	222.60M	189.38M	159.86M	181.28M	140.53M
Selling, General & Administrative	172.31M	208.57M	235.91M	197.72M	142.35M	169.91M	231.24M
Operating Income (EBIT)	-240.64M	-321.36M	-324.01M	-254.15M	-185.20M	-213.75M	-188.78M
Operating Margin	-126.7%	-146.3%	-108.2%	-93.5%	-75.9%	-70.0%	-42.8%
Income Before Tax (EBT)	-235.24M	-666.63M	-314.43M	-220.97M	-183.62M	-250.86M	-183.53M
Interest Income	6.60M	14.33M	9.68M	277K	255K	6.24M	5.25M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	5.40M	-345.27M	9.58M	33.18M	1.58M	-37.11M	5.25M
Net Income	-280.88M	-666.70M	-311.66M	-217.49M	-183.36M	-250.86M	-183.53M
Income Tax Expense	-41K	73K	-2.77M	-3.48M	0.00	0.00	0.00
Net Profit Margin	-147.9%	-303.5%	-104.1%	-80.0%	-75.2%	-82.1%	-41.6%
EBITDA	-217.29M	-291.87M	-287.51M	-228.00M	-164.95M	-191.51M	-178.88M
EBITDA Margin	-114.4%	-132.9%	-96.0%	-83.9%	-67.6%	-62.7%	-40.6%
Depreciation & Amortization	23.35M	29.48M	36.50M	26.15M	20.25M	22.25M	9.90M
EPS Basic	-10.88	-27.59	-13.81	-9.96	-9.02	-14.24	-9.03
EPS Diluted	-10.88	-28.01	-13.80	-9.96	-9.02	-14.24	-9.03
Shares Outstanding	25.82M	24.17M	22.58M	21.83M	20.32M	20.32M	20.32M
Diluted Shares Outstanding	25.82M	23.80M	22.58M	21.83M	20.32M	20.32M	20.32M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.